(Q37857866)

24 August 2017

1 reference

title

Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism (English)

1 reference

24 August 2017

Aris P Agouridis

1

1 reference

24 August 2017

Theodosios D Filippatos

series ordinal

2

1 reference

24 August 2017

Vasilios Tsimihodimos

series ordinal

3

1 reference

24 August 2017

Moses S Elisaf

series ordinal

4

1 reference

24 August 2017

publication date

1 March 2011

1 reference

Expert Review of Cardiovascular Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

9

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

355-366

1 reference

Lipid-lowering drugs acting at the level of the gastrointestinal tract

24 August 2017

cites work

1 reference

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials

21 January 2018

1 reference

Pleiotropic effects of ezetimibe: do they really exist?

21 January 2018

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

Statin-associated adverse effects beyond muscle and liver toxicity

21 January 2018

1 reference

Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia

21 January 2018

1 reference

Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia

21 January 2018

1 reference

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review

21 January 2018

1 reference

Combination of fenofibrate with non-statin drug regimens.

21 January 2018

1 reference

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia

21 January 2018

1 reference

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia

21 January 2018

1 reference

Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

21 January 2018

1 reference

Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia

21 January 2018

1 reference

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

21 January 2018

1 reference

An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?

21 January 2018

1 reference

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

21 January 2018

1 reference

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

21 January 2018

1 reference

Efficacy and safety of ezetimibe/simvastatin co- administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome

21 January 2018

1 reference

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate

21 January 2018

1 reference

Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia

21 January 2018

1 reference

21 January 2018

Niacin and laropiprant

1 reference

Extended-release niacin (nicotinic acid)/laropiprant

21 January 2018

1 reference

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia

21 January 2018

1 reference

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia

21 January 2018

1 reference

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome

21 January 2018

1 reference

Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering.

21 January 2018

1 reference

Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels

21 January 2018

1 reference

Orlistat-associated adverse effects and drug interactions: a critical review

21 January 2018

1 reference

The effects of orlistat on metabolic parameters and other cardiovascular risk factors.

21 January 2018

1 reference

Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.

21 January 2018

1 reference

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

21 January 2018

1 reference

Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome

21 January 2018

1 reference

The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma

21 January 2018

1 reference

New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma

21 January 2018

1 reference

Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women

21 January 2018

1 reference

Paraoxonase and coronary heart disease

21 January 2018

1 reference

Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

21 January 2018

1 reference

The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.

21 January 2018

1 reference

Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia

21 January 2018

1 reference

Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes

21 January 2018

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Pleiotropic effects of thiazolidinediones

21 January 2018

1 reference

Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients

21 January 2018

1 reference

Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders

21 January 2018

1 reference

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERC.11.4

1 reference

24 August 2017

1 reference